Amgen
AMGN
$377.35
-1.34%
Amgen Inc. is a global biotechnology company that develops and manufactures human therapeutics for serious illnesses, including cancer, kidney disease, inflammatory conditions, and rare diseases, with a growing portfolio of biosimilars. As one of the world's largest independent biotech firms, Amgen holds a leadership position in biologics, leveraging its scale and R&D capabilities to compete across multiple therapeutic areas. The current investor narrative centers on the company's pipeline innovation, particularly the once-monthly obesity candidate MariTide, which faces intense competition from Eli Lilly and Novo Nordisk, while regulatory scrutiny of its rare disease drug Tavneos and the impact of potential drug tariffs add layers of risk and debate around the stock's growth trajectory.…
AMGN
Amgen
$377.35
Related headlines
Investment Opinion: Should I buy AMGN Today?
Based on the analysis, I rate Amgen as a Hold. The stock has strong fundamentals with accelerating revenue growth and improving margins, but it is trading above the average analyst target of $388.48, implying limited upside. The consensus recommendation is 'Buy' with a mean rating of 2.47, but the average target suggests a -11.2% downside, indicating the stock has run ahead of fundamentals.
Sign up to view all
AMGN 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Amgen's fundamentals are solid, with accelerating revenue growth and improving margins, but the stock has rallied significantly and now trades above analyst targets. The key factors are the balance between growth prospects and valuation. If MariTide succeeds, the stock could see further upside, but if regulatory or competitive risks materialize, it could decline. The stance would upgrade to bullish if the stock pulls back to the average target or if MariTide data is overwhelmingly positive, and downgrade to bearish if revenue growth decelerates below 5% or if Tavneos issues escalate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $388.03 and implied upside of +2.8% versus the current price.
Average Target
$388.03
0 analysts
Implied Upside
+2.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$225 - $457
Analyst target range
Amgen is covered by 29 analysts, with a consensus recommendation of 'Buy' and a mean rating of 2.47 (where 1 is Strong Buy and 5 is Sell). The average price target is $388.48, which implies a downside of -11.2% from the current price of $437.23, indicating that the stock has surpassed analyst expectations and may be ahead of fundamentals. The target range spans from a low of $230.00 to a high of $457.00, with the high target suggesting potential upside of 4.5%, while the low target implies a -47.4% downside, reflecting significant uncertainty. Recent ratings from firms like UBS (Buy) and Morgan Stanley (Equal Weight) show a mix of optimism and caution, and the wide spread between low and high targets highlights the debate over Amgen's pipeline potential and regulatory risks.
Bulls vs Bears: AMGN Investment Factors
Amgen presents a compelling bull case with accelerating revenue growth, improving profitability, and a promising pipeline, particularly MariTide. However, the stock has rallied significantly and now trades above the average analyst target, raising valuation concerns. The bear case highlights high debt, regulatory risks from Tavneos, and intense competition in the obesity market. Currently, the bull case has stronger evidence given the strong fundamental performance and low beta, but the key tension is whether the stock's momentum can be sustained given its premium valuation and the potential for regulatory or competitive setbacks. The resolution of MariTide's clinical and commercial success and the outcome of Tavneos regulatory issues will likely determine the stock's trajectory.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 5.76% YoY to $8.618B, following 9.0% growth in Q4 2025 and 12.4% in Q3 2025, indicating a robust multi-quarter acceleration trend. This is driven by key products like Prolia, Otezla, and newer launches such as TEPEZZA and TEZSPIRE.
- Strong Profitability and Margin Expansion: Net margin improved to 21.1% in Q1 2026 from 13.5% in Q4 2025, with EPS of $3.37. Operating margin of 29.1% and gross margin of 68.2% demonstrate efficient cost management and pricing power.
- Attractive Valuation on Forward Earnings: Forward P/E of 17.91x is at a 3% discount to the industry average of 18.5x, while PEG ratio of 0.26 suggests the market is pricing in significant earnings growth. Trailing P/E of 22.84x is near the lower end of its 2-year range (11.4x-55.7x).
- Pipeline Optionality with MariTide: MariTide, a once-monthly obesity candidate, offers significant upside potential. While facing competition from LLY and NVO, its convenience could carve a niche, and positive clinical data could drive substantial revenue growth.
Bearish
- Stock Trades Above Analyst Targets: Current price of $437.23 is 12.6% above the average analyst target of $388.48, implying a -11.2% downside. The stock has surged past expectations, suggesting it may be overextended in the short term.
- High Debt Levels: Debt-to-equity ratio of 6.31x is extremely high, reflecting the significant debt taken on for the Horizon acquisition. Interest expense of $657M in Q1 2026 weighs on net income and increases financial risk.
- Regulatory and Safety Concerns for Tavneos: FDA warnings about fatal liver risks and global regulatory scrutiny over data manipulation pose significant risks to Tavneos. This could lead to restrictions, lawsuits, and reputational damage, impacting rare disease revenue.
- Intense Competition in Obesity Market: MariTide faces fierce competition from Eli Lilly and Novo Nordisk, who have established products and significant market share. Pfizer is also entering the space, increasing competitive pressure.
AMGN Technical Analysis
Amgen's stock is in a powerful uptrend, with a 1-year price change of +56.1% and a 3-month gain of +25.1%, significantly outperforming the S&P 500's 18.65% and 4.43% gains over the same periods. The current price of $437.23 sits near the top of its 52-week range, at approximately 97.8% of the high of $447.03, indicating strong momentum and bullish sentiment, though it also suggests the stock may be overextended in the short term. The 52-week low of $269.77 provides a clear support level, and the stock's position near the highs reflects a market rewarding the company's pipeline progress and defensive characteristics.
Beta
0.43
0.43x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$270-$447
Price range past year
Annual Return
+33.5%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | -9.3% | -1.1% |
| 3m | +6.2% | +3.0% |
| 6m | +3.0% | +15.4% |
| 1y | +33.5% | +16.2% |
| ytd | +15.2% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Amgen's revenue growth is accelerating, with Q1 2026 revenue of $8.618 billion up 5.76% year-over-year, following a 9.0% increase in Q4 2025 and a 12.4% jump in Q3 2025, indicating a robust multi-quarter trend. The growth is driven by key products like Prolia ($1.054B), Otezla ($625M), and EVENITY ($599M), while newer launches such as TEPEZZA ($457M) and TEZSPIRE ($474M) contribute to diversification. The company's gross margin of 68.2% in Q1 2026 is slightly below the 70.8% trailing average, but net income of $1.819 billion and EPS of $3.37 show solid profitability, with a net margin of 21.1% that has improved from 13.5% in Q4 2025.
Quarterly Revenue
$8.6B
2026-03
Revenue YoY Growth
+5.8%
YoY Comparison
Gross Margin
68.2%
Latest Quarter
Free Cash Flow
$8.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Given Amgen's positive net income, the trailing P/E ratio of 22.84x is the primary valuation metric, while the forward P/E of 17.91x implies the market expects significant earnings growth, supported by a PEG ratio of 0.26. Compared to the industry average P/E of 18.5x (from valuation data), Amgen trades at a 23% premium on trailing earnings, but the forward P/E is at a 3% discount, suggesting the market is pricing in above-average growth. Historically, Amgen's trailing P/E has ranged from 11.4x to 55.7x over the past two years, and the current 22.84x is near the lower end of that range, indicating the stock is not overly expensive relative to its own history, especially given its strong growth prospects.
PE
22.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated due to Amgen's high debt load, with a debt-to-equity ratio of 6.31x, a result of the Horizon acquisition. Interest expenses of $657 million in Q1 2026 reduce net income, and the company's net margin of 21.1% is sensitive to interest rate changes. Revenue concentration in mature products like Prolia and Otezla, which face biosimilar competition, poses a risk, though newer drugs like TEPEZZA and TEZSPIRE are diversifying the portfolio. The company's free cash flow of $8.6 billion TTM provides a cushion, but continued high R&D spending ($1.7B in Q1) is necessary to sustain pipeline growth.